The authors aimed to determine the effect of probiotics in the treatment and prevention of acute infectious diarrhoea in infants and children.
Other Publications of Related Interest). Two reviewers independently assessed validity and resolved any disagreements by discussion. Inter-reviewer agreement on study quality was measured using weighted kappa statistics.
Data extraction
One reviewer extracted the data using a standardised form and a second reviewer checked the extraction. Information on the following was tabulated: country of study; study setting for prevention studies; inclusion and exclusion criteria; age range of participants; probiotic strain and dose; intervention regimen; outcomes assessed; and aetiology or type of diarrhoea.
Risk ratios (RR) and 95% confidence intervals (CIs) between the intervention and placebo groups were calculated for the presence of diarrhoea on day 3 for each study.
Methods of synthesis
How were the studies combined?
The pooled RR (and 95% CI) between probiotics and placebo was calculated for the presence of diarrhoea on day 3 using fixed-effect and random-effects models. The pooled weighted mean difference (WMD) of the duration of diarrhoea between probiotics and placebo was calculated, along with the 95% CI, with weighting based on the inverse of the variance. The number-needed-to-treat (NNT) was calculated, along with the 95% CI. The data were expressed as patient-months and incidence rate of diarrhoea cases per patient-months in the probiotic and placebo groups, and the incidence rate ratio of diarrhoea was then estimated.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared statistic. Subgroup analyses were used to explore the influence of the type of probiotic and the aetiology of the diarrhoea (viral versus bacterial). A sensitivity analysis was used to explore potential sources of significant heterogeneity.
Results of the review
Ten RCTs (at least 733 children) of treatment and 3 RCTs of prevention (340 children) were included.
Inter-rater agreement on study selection and study quality was good (kappa 0.72 for selection and 0.78 for quality). The quality scores ranged from 3 to 5 (median 4) out of a potential 5 points.
Treatment of diarrhoea.
Compared with placebo, probiotics significantly reduced the risk of diarrhoea lasting more than 3 days; the RR (8 RCTs, 731 children) was 0.43 (95% CI: 0.34, 0.53) with the fixed-effect model. No significant heterogeneity was detected (P=0.12). In terms of the influence of the probiotic strain, only LGG consistently significantly reduced the risk of diarrhoea lasting more than 3 days; the RR (3 RCTs, 397 children) was 0.49 (95% CI: 0.36, 0.66) with the fixedeffect model. The NNT with LGG to avoid one case of diarrhoea lasting more than 3 days was 4 (95% CI: 3, 9) when using a conservative random-effects model. The NNT for Saccharomyces boulardii (1 RCT) was 2 (95% CI: 2, 3). It was not possible to explore the influence of aetiology of diarrhoea due to the lack of appropriate data.
Compared with placebo, probiotics significantly reduced the duration of diarrhoea; the pooled WMD (8 RCTs, 733 children) was -18.2 hours (95% CI: -26.9, -9.5) with the random-effects model. Significant heterogeneity was detected (P=0.015). Heterogeneity appeared to be due to one RCT reporting no significant difference between unspecified strains of Streptococcus thermophilus, L. acidophilus, and L. bulgaricus and placebo. Excluding this RCT resulted in homogeneity. A meta-analysis of 4 RCTs (297 children with, predominantly, confirmed rotavirus diarrhoea) found that probiotics (LGG and L. reuteri) significantly reduced the duration of diarrhoea compared with placebo; the pooled WMD was -24.8 hours (95% CI: -31.8, -17.9, P<0.001). No significant heterogeneity was detected (P=0.82). A subset analysis of 53 children with invasive enteric infections from one RCT found no significant difference between probiotics and placebo; the WMD was 1.3 hours (95% CI: -15.3, 17.9).
Prevention of diarrhoea.
